Expert Review of Clinical Immunology最新文献_第8页

Innovative cell therapies for systemic sclerosis: available evidence and new perspectives 治疗系统性硬化症的创新细胞疗法：现有证据和新视角

IF 4.4 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-16 DOI: 10.1080/1744666x.2024.2402494

Alain Lescoat, Monalisa Ghosh, Stephan Kadauke, Dinesh Khanna

引用次数: 0

Updating on pregnancy in rheumatoid arthritis. 类风湿关节炎患者怀孕的最新情况。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-20 DOI: 10.1080/1744666X.2024.2356164

Carlotta Schenone, Greta Pacini, Emanuele Gotelli, Elvis Hysa, Rosanna Campitiello, Silvia Sammorì, Sabrina Paolino, Alberto Sulli, Maurizio Cutolo

{"title":"Updating on pregnancy in rheumatoid arthritis.","authors":"Carlotta Schenone, Greta Pacini, Emanuele Gotelli, Elvis Hysa, Rosanna Campitiello, Silvia Sammorì, Sabrina Paolino, Alberto Sulli, Maurizio Cutolo","doi":"10.1080/1744666X.2024.2356164","DOIUrl":"10.1080/1744666X.2024.2356164","url":null,"abstract":"Introduction: Rheumatoid arthritis (RA), the most prevalent autoimmune disease in reproductive years, exhibits a higher incidence in females, suggesting involvement of estrogens, genetics and environmental factors in disease onset. Literature shows smaller families in RA patients, driving increased interest in Assisted Reproductive Techniques.Areas covered: This review elucidates how immunotolerance mechanisms contribute to favorable pregnancy outcomes in RA, emphasizing the need for a careful pregnancy planning to mitigate fetal complications and postnatal flares, which surpass those in the general population. A thorough medication evaluation, orchestrated by a multidisciplinary team, is imperative during pregnancy, weighing potential teratogenic effects against safer alternatives to balance medication safety with disease control. A systematic literature search on PubMed and MEDLINE, using specific terms, covered relevant academic journals up to the latest date.Expert opinion: This narrative review comprehensively addresses pregnancy-related considerations in RA patients, prioritizing meticulous disease management with pregnancy and breastfeeding-compatible drugs in line with the latest recommendations and registry data. The focus remains on evaluating glucocorticoids, conventional, and biological disease-modifying drugs for compatibility during pregnancy and breastfeeding. Additionally, the evolving landscape of targeted synthetic drugs during pregnancy is explored, providing insights into the latest developments in rheumatological care.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1041-1052"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Can we define difficult-to-treat systemic sclerosis? 我们能否定义难以治疗的系统性硬化症？

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-14 DOI: 10.1080/1744666X.2024.2352450

Gabriella Szűcs, Zoltán Szekanecz, Szilvia Szamosi

{"title":"Can we define difficult-to-treat systemic sclerosis?","authors":"Gabriella Szűcs, Zoltán Szekanecz, Szilvia Szamosi","doi":"10.1080/1744666X.2024.2352450","DOIUrl":"10.1080/1744666X.2024.2352450","url":null,"abstract":"Introduction: Systemic sclerosis (SSc) is a chronic autoimmune rheumatic disease characterized by microvascular alterations, immunopathology, and widespread fibrosis involving various organs. It is considered difficult to treat due to several reasons: complex pathogenesis, heterogeneity, late diagnosis, limited treatment options for certain organ manifestations, lack of personalized medicine.Areas covered: This review presents the heterogeneity, survival and organ manifestations with their risk factors of systemic sclerosis and their current treatment options, while drawing attention to difficult-to-treat forms of the disease, based on literature indexed in PubMed.Expert opinion: Despite recent advances in the management of SSc over the last decades, the disease presents significant morbidity and mortality. Although available treatment protocols brought significant advancements in terms of survival in SSc-associated interstitial lung disease and pulmonary arterial hypertension, less success has been achieved in the treatment of Raynaud's phenomenon and digital ulcers and the results are modest in case of heart, gastrointestinal, and renal manifestations. There are patients who do not respond to treatment and deteriorate even with adequate therapy. They can be considered difficult-to treat (D2T) cases. We have created a possible score system based on the individual organ manifestations and highlighted treatment options for the D2T SSc category.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1065-1081"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140854850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunology and targeted therapy in Castleman disease. 卡斯特曼病的免疫学和靶向治疗。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1080/1744666X.2024.2357689

Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki

{"title":"Immunology and targeted therapy in Castleman disease.","authors":"Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki","doi":"10.1080/1744666X.2024.2357689","DOIUrl":"10.1080/1744666X.2024.2357689","url":null,"abstract":"Introduction: Castleman disease (CD) is a benign lymphoproliferative disease causing severe systemic inflammation. Interleukin-6 (IL-6) is a major pathogenesis of multicentric CD (MCD), but only 30-60% of patients respond to IL-6 inhibitors. Novel agents for IL-6 inhibitor-refractory cases are needed. Clinical data and samples are being collected on a large scale and the clinical, pathological, and pathogenetic aspects are being elucidated.Areas covered: The pathological and clinical classification of CD is outlined. Focusing on idiopathic MCD (iMCD), this review identifies therapeutic targets and summarizes currently recommended drugs and promising therapeutic candidates.Expert opinion: The pathogenesis of MCD has been implicated in the activation of the Janus kinase (JAK)-transcriptional signaling activator (STAT) 3 pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt/mechanical target of rapamycin (mTOR) signaling pathway. iMCD-TAFRO (thrombocytopenia, anasarca, fever/elevated CRP, reticulin myelofibrosis/renal dysfunction, organ enlargement) is resistant to IL-6 inhibitors, and cyclosporine and mTOR inhibitors are sometimes effective. JAK inhibitors and mTOR inhibitors may be therapeutic agents for iMCD. Recently, we have shown that peripheral helper T (Tph) cell abnormalities are at the core of iMCD pathogenesis. Therapies targeting chemokine (C-X-C motif) ligand 13 (CXCL13) produced by Tph cells and blocking the Tph-CXCL13-B cell pathway may satisfy unmet need in refractory cases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1101-1112"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling. 特应性皮炎分层：皮肤和血液转录组学与蛋白质组学分析的现状与未来展望。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-03-04 DOI: 10.1080/1744666X.2024.2323964

Kelly Hawkins, Eden David, Jacob W Glickman, Ester Del Duca, Emma Guttman-Yassky, James G Krueger

{"title":"Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling.","authors":"Kelly Hawkins, Eden David, Jacob W Glickman, Ester Del Duca, Emma Guttman-Yassky, James G Krueger","doi":"10.1080/1744666X.2024.2323964","DOIUrl":"10.1080/1744666X.2024.2323964","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a common, chronic inflammatory skin disorder driven by an intricate interplay of genetic, environmental, and immunological factors.Areas covered: As a clinically heterogenous condition, AD may be stratified into subtypes based on factors including, chronicity, immunoglobulin E levels, severity, age, and ethnicity. Transcriptomic and proteomic analyses in skin and blood help elucidate the underlying molecular mechanisms of these AD subtypes, referred to as AD endotypes. Further characterizing AD endotypes using reliable biomarkers can facilitate the development of more effective and personalized therapeutics and improve our tools for monitoring disease progression and therapeutic response across a diverse subset of patients. Here, we aim to provide perspective on the latest research regarding AD stratification using skin and blood-based studies and insight into the implications of these findings on the future of AD research and clinical practice.Expert opinion: The precise stratification of AD endotypes will allow for the development of reliable biomarkers and a more personalized medical treatment approach. Clinical practice and trials will eventually be able to bridge clinical with molecular data to optimize individualized treatments and more effectively monitor treatment response.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1083-1088"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease. 拓宽巨细胞动脉炎的临床范围：从典型的颅内疾病到以颅外为主的疾病模式。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-21 DOI: 10.1080/1744666X.2024.2356741

Miguel Ángel González-Gay, Elena Heras-Recuero, Teresa Blázquez-Sánchez, Claritza Caraballo-Salazar, Fernando Rengifo-García, Santos Castañeda, Raquel Largo

{"title":"Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease.","authors":"Miguel Ángel González-Gay, Elena Heras-Recuero, Teresa Blázquez-Sánchez, Claritza Caraballo-Salazar, Fernando Rengifo-García, Santos Castañeda, Raquel Largo","doi":"10.1080/1744666X.2024.2356741","DOIUrl":"10.1080/1744666X.2024.2356741","url":null,"abstract":"Introduction: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis that affects people aged 50 years and older. Classically, GCA was considered a disease that involved branches of the carotid artery. However, the advent of new imaging techniques has allowed us to reconsider the clinical spectrum of this vasculitis.Areascovered: This review describes clinical differences between patients with the cranial GCA and those with a predominantly extracranial LV-GCA disease pattern. It highlights differences in the frequency of positive temporal artery biopsy depending on the predominant disease pattern and emphasizes the relevance of imaging techniques to identify patients with LV-GCA without cranial ischemic manifestations. The review shows that so far there are no well-established differences in genetic predisposition to GCA regardless of the predominant phenotype.Expert commentary: The large branches of the extracranial arteries are frequently affected in GCA. Imaging techniques are useful to identify the presence of 'silent' GCA in people presenting with polymyalgia rheumatica or with nonspecific manifestations. Whether these two different clinical presentations of GCA constitute a continuum in the clinical spectrum of the disease or whether they may be related but are definitely different conditions needs to be further investigated.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1089-1100"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the crossroads: asthma, trained immunity, and infection susceptibility. 十字路口的导航：哮喘、训练有素的免疫力和感染易感性。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-09 DOI: 10.1080/1744666X.2024.2353743

Ahmad Z Al Meslamani, Eman Merghani Ali

引用次数: 0

Lymphocyte-C-reactive protein ratio combined with albumin upon admission predicts coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease: a retrospective cohort study. 淋巴细胞-C反应蛋白比值与白蛋白结合可预测川崎病儿科患者的冠状动脉扩张和动脉瘤形成：一项回顾性队列研究。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1080/1744666X.2024.2385765

Yajun Wang, Yilu Lin, Lei Zhang, Di Wu, Yujia Tang, Huan Meng, Huiying Liu, Xiaohui Jiang, Guoli Zhang, Yang Yang, Fengmei Li, Yajun Shu, Kai Kang, Ligang Si, Yang Gao

{"title":"Lymphocyte-C-reactive protein ratio combined with albumin upon admission predicts coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease: a retrospective cohort study.","authors":"Yajun Wang, Yilu Lin, Lei Zhang, Di Wu, Yujia Tang, Huan Meng, Huiying Liu, Xiaohui Jiang, Guoli Zhang, Yang Yang, Fengmei Li, Yajun Shu, Kai Kang, Ligang Si, Yang Gao","doi":"10.1080/1744666X.2024.2385765","DOIUrl":"10.1080/1744666X.2024.2385765","url":null,"abstract":"Background: We aimed to explore simple and effective clinical parameters or combinations to predict coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease (KD).Design and methods: This retrospective cohort study included pediatric patients with KD from January, 2013 to December, 2022. Multiple demographic and clinical data were collected, collated, and calculated from the medical records. Then they were divided into the coronary artery dilation and aneurysm formation group or the non-coronary artery dilation and aneurysm formation group. Lymphocyte-C-reactive protein ratio (LCR) was transformed into its natural logarithm and expressed as lnLCR.Results: A total of 64 pediatric patients with KD were enrolled in this cohort study after 1:3 propensity score matching (PSM). For each unit increase in lnLCR, the possibility of coronary artery dilation and aneurysm formation decreased to 0.419 times the original value. The areas under the receiver operating characteristic (ROC) curves of lnLCR combined with albumin (ALB), ALB, and lnLCR to classify pediatric patients with KD into the coronary artery dilation and aneurysm formation group were 0.781, 0.692, and 0.743, respectively.Conclusion: LCR combined with ALB upon admission is a promising predictor of coronary artery dilation and aneurysm formation in pediatric patients with KD.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1127-1133"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CSE1L as a prognostic biomarker associated with pan cancer immune infiltration and drug sensitivity. CSE1L 是与泛癌免疫浸润和药物敏感性相关的预后生物标志物。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-23 DOI: 10.1080/1744666X.2024.2356747

Haiyang Li, Lingwa Wang, Zhaohui Ruan, Xiaoyan Li, Yifan Yang, Jugao Fang, Ru Wang

{"title":"CSE1L as a prognostic biomarker associated with pan cancer immune infiltration and drug sensitivity.","authors":"Haiyang Li, Lingwa Wang, Zhaohui Ruan, Xiaoyan Li, Yifan Yang, Jugao Fang, Ru Wang","doi":"10.1080/1744666X.2024.2356747","DOIUrl":"10.1080/1744666X.2024.2356747","url":null,"abstract":"Background: Rising cancer-related mortality underscores the importance of biomarkers for treatment and prognosis, with Chromosome Segregation 1 Like (CSE1L) linked to various cancers yet its roles remain partially understood. This study investigates CSE1L's expression and oncogenic mechanisms in solid tumors.Research design and methods: We analyzed multi-omics data from 31 solid tumors, measured CSE1L in 41 head and neck carcinoma patients post-chemotherapy via qRT-PCR, and evaluated the impact of CSE1L knockdown on cell proliferation in A549 and HepG2 cells.Results: In this study, we observed significantly elevated levels of CSE1L RNA in 13 tumor tissues and protein levels in 8 tumor tissues compared to their corresponding adjacent normal tissues. Additionally, our investigation unveiled a correlation between heightened CSE1L expression in tumor tissues and worsened patient prognosis, poor response to immunotherapy, and diminished effectiveness of neoadjuvant chemotherapy. Through an analysis of CSE1L mechanisms, we discovered its potential involvement in promoting tumor cell proliferation, enhancing drug resistance, and influencing immune infiltration, thereby impacting patient prognosis and treatment outcomes. Finally, we delved into the potential mechanisms underlying upregulation of CSE1L in tumor tissues.Conclusion: Our findings demonstrate that CSE1L promotes tumor development in various malignancies, highlighting its potential as both a therapeutic target and prognostic indicator.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1113-1125"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How could our genetics impact COVID-19 vaccine response? 我们的基因如何影响 COVID-19 疫苗的反应？

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-04-27 DOI: 10.1080/1744666X.2024.2346584

Keyi Zheng, Amanda Y Chong, Alexander J Mentzer

{"title":"How could our genetics impact COVID-19 vaccine response?","authors":"Keyi Zheng, Amanda Y Chong, Alexander J Mentzer","doi":"10.1080/1744666X.2024.2346584","DOIUrl":"10.1080/1744666X.2024.2346584","url":null,"abstract":"Introduction: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has posed unprecedented global health challenges since its emergence in December 2019. The rapid availability of vaccines has been estimated to save millions of lives, but there is variation in how individuals respond to vaccines, influencing their effectiveness at an individual, and population level.Areas covered: This review focuses on human genetic factors influencing the immune response and effectiveness of vaccines, highlighting the importance of associations across the HLA locus. Genome-Wide Association Studies (GWAS) and other genetic association analyses have identified statistically significant associations between specific HLA alleles including HLA-DRB1*13, DBQ1*06, and A*03 impacting antibody responses and the risk of breakthrough infections post-vaccination. Relationships between these associations and potential mechanisms and links with risks of natural infection or disease are explored, and this review concludes by emphasizing how understanding the mechanisms of these genetic determinants may inform the development of tailored vaccination strategies.Expert opinion: Although complex, we believe these findings from the SARS-CoV2 pandemic offer a unique opportunity to understand the relationships between HLA and infection and vaccine response, with a goal of optimizing individual protection against COVID-19 in the ongoing pandemic, and possibly influencing wider vaccine development in the future.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1027-1039"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0